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Abstract 
A case-control study investigating the association between plasna 
lipids and breast cancer was conducted in Buffalo, New York. Women aged 
30-80 conpleted a questionnaire and donated a fasting blocxi sample prior 
to diagnostic breast biopsies. '!he 83 women fO\.li'Xl to have breast cancer 
(cases) had significantly higher plasna triglyceride values than did the 
113 women fO\.li'Xl not to have breast cancer (controls). I.ower beta-
carotene values were associated with breast cancer, but only in those 
women with elevated triglyceride or cholesterol. Plasna cholesterol 
values were lower in those breast cancer cases presenting with a more 
advanced stage of disease suggesting that metabolic effects of clinical 
and preclinical breast cancer may lower cholesterol levels. The 
obseJ:vation of a positive association with triglycerides and a negative 
association with beta-carotene is consistent with the hypothesis that 
women who develop breast cancer may consume diets higher in total and 
saturated fat, and lower in carotene-rich vegetables. 
Running title: Breast cancer and plasna lipids 
Key Words: Breast cancer, benign breast disease, plasna, diet, 
cholesterol, triglyceride, beta-carotene 
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Introduction 
Much research has been devoted to the association between breast 
cancer and various indicators of fat consumption. A number of 
ecological studies have shovm a direct association between breast cancer 
rates and per capita fat intake (1-6), total fat estimated from a food 
frequency questionnaire (7), and animal but not vegetable fat (8,9). 
Results from analytical studies of individuals, however, have been 
inconsistent. Investigators have generally reported no significant 
association between total dietary fat intake and breast cancer ( 10-17) , 
although a few studies have shovm weak direct associations ( 18, 19) . 
Most ecological studies (20-22) and analytical studies (23-28) using 
food items have suggested that diets more frequently including foods 
high in total and saturated fat are associated with breast cancer. One 
other investigation (29) reported no association between consumption of 
high fat food items and fatal breast cancer. other research of 
individuals using estimated dietary intake of saturated fat have been 
equivocal (11,13,14,18). In surrnnary, ecological studies generally 
indicate a direct association between breast cancer and total and 
saturated fat, while analytical studies have found either a weak 
association or none at all. 
The relationship between plasma cholesterol levels and breast cancer 
is also unclear. Investigations using case-control designs report 
higher (30) , lower (31) and similar plasma cholesterol levels (32) in 
breast cancer cases compared with controls. An inverse association 
between plasma cholesterol and overall cancers in women has been 
suggested in two cohort studies (33,34); however, the differences 
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between cases and controls were not statistically significant. 'IWo 
prospective studies (35, 36) reported significantly higher cholesterol 
values among women who later developed breast cancer, while two other 
prospective studies (37 ,38) fourrl no association. However, further 
analyses of these data revealed a terrlency for cholesterol values to be 
lower in women with breast cancer (39), or in women with overall cancers 
(36,40) when that cancer was diagnosed less than two years after the 
blood sample was drawn. 'Ihese results support the concept that 
preclinical cancer can lower serum cholesterol. 
'!he inconsistencies noted in the studies of dietary fat and breast 
cancer may be related, in part, to the oftentimes serious limitations of 
dietary methodology (41-43). In theo:ry, one approach which may obviate 
this difficulty might be the use of metabolic indicators of the 
consumption of high fat diets. We, therefore, investigated the 
association between two plasma lipids and breast cancer. Although 
plasma triglycerides and cholesterol do not always reflect dieta:ry 
intake, high levels of these lipids are consistent with high total and 
saturated fat dieta:ry patterns ( 44-53) . '!he inconsistencies in the 
plasma cholesterol studies and the suggestion of a preclinical effect 
warranted further investigation because the effect of disease on 
circulating levels of cholesterol would be of methodological interest to 
epidemiological studies obtaining blood samples on cancer patients. In 
addition, because of the interest in beta-carotene and cancer risk (54) 
and because beta-carotene may be an important anti -oxidant against lipid 
peroxidation (55), the relationships between plasma beta-carotene and 
plasma lipids and cancer risk were investigated. 
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Methods 
Between September 1985 arrl September 1986, women were enrolled from 
the breast clinic at Roswell Park Memorial Institute, arrl from the 
offices of two private surgeons in Buffalo, New York. Eligible patients 
were 30 to 80 years of age, had no previous histo:ry of cancer arrl had 
lived in upstate New York or Pennsylvania for at least one year. After 
subjects were scheduled for a diagnostic biopsy, infonned consent was 
obtained arrl they were given a questionnaire arrl directions for the 
blood collection proc:edure. '!he self-administered questionnaire 
ascertained info:nnation regarding the subjects' medical and reproductive 
histo:ry. 
Patients were classified into one of three groups based on their 
pathology reports from the diagnostic breast biopsies; cases (n=83) , 
controls (n=113) or excluded (n=40). Patients with biopsy reports that 
described lesions thought to be at increased risk of breast cancer, 
predominantly of an atypical hyperplastic nature, were excluded from the 
control group because these lesions, though not rna.lignant, are thought 
to correlate with much higher risk of subsequent breast cancer (56-58). 
SUbjects with the remaining benign lesions, such as lipomas or fibromas, 
were included in the control group, as well as 34 patients who completed 
the diagnostic workup, but were detennined not to have rna.sses requiring 
biopsy. 
Fasting blood samples were drawn from subjects prior to their 
biopsies, or on a designated day for the 34 patients without biopsies. 
'!he samples were centrifuged, plasma was preserved in scxiium asco:rbate 
(10 ngjml plasma) arrl frozen at -80° until all samples had been 
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collected. Samples were thawed once for portioning of aliquots and once 
for the laborato:ry analysis. Triglycerides were analyzed by a manual 
colorimetric methcxi (59) and total cholesterol was assessed using a 
spectrophotometric kit methcxi (Sigma Chemical Co., St. I..ouis, ID). 
Statistical analyses were perfonned using SYSTAT (version 3. o, 
Systat, 1985) and the supplementa:ry legit module on an AT&T 6300 
Personal Conputer. Differences in means were tested with the student's 
t-test. Nutrients were log-transfonned and categorized into quartiles 
based on the distribution in the controls. Multivariate legit analyses 
were conducted with case status as the dependent variable; there were 
three possible outcome categories but only the case versus control 
results are presented here. In the mu1 ti variate analyses, the non-
nutrient breast cancer risk factors used as covariates were age, age at 
menarche, age at menopause, age at first birth, parity, menopausal 
status, family histo:ry in a first degree relative, Quetelet's index, 
marital status and income. The legit models and variables were assessed 
using the log likelihood ratio test. Tests for trend were conducted 
using the continuous fonn of the nutrient variable in the legit analyses 
and in the ordina:ry least squares regression of stage of disease on the 
nutrient of interest. A general stage variable was used with 4 
categories (In situ, Stage I, Stage II, and Stage III & IV) , and a more 
specific stage variable was created with 20 ordinal categories based on 
the severity of disease designated from categories in the standard T-N-M 
staging fonn ( 60) . 
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Results 
eorrparisons of the baseline characteristics for the cases and 
controls has indicated (61) that the cases were significantly older than 
the controls. Many of the known breast cancer risk factors (such as 
family histo:ry of breast cancer, higher weight, earlier age at menarche) 
were not more prevalent in cases than in controls, suggesting that these 
controls were at high-risk for breast cancer. Therefore, this study 
compared women with breast cancer to women at high-risk for breast 
cancer. 
A comparison of the mean cholesterol levels (Table 1) indicated no 
differences between cases and controls, however there was a significant 
trend of decreasing cholesterol with increasing stage of breast cancer. 
Mean triglyceride levels for controls were lower than for cases 
(p=O.OOl). A slight trend of decreasing triglyceride levels is apparent 
with more advanced stage of disease, however this trend is not 
statistically significant (p=0.20). 
The unadjusted logit model indicated no association between 
cholesterol and breast cancer (Table 2), but adjustment for the other 
risk factors and for other nutrients (triglyceride and beta-carotene) 
indicated a statistically significant association. Although not 
apparent from the odds ratios, a significant test for trend indicated an 
increasing risk of being a case associated with decreasing cholesterol 
values (test for trend p=0.03). Therefore, lower cholesterol values were 
associated with case status. 
'!he unadjusted model for triglycerides indicated a significant trend 
of decreasing risk with decreasing triglyceride values (Table 3). 
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Adjusbnent for the other risk factors diminished this association, 
hO'iNever the best-fit model included the other nutrients and predicted a 
4-fold increased risk of breast cancer in the highest compared with the 
lO'iNest triglyceride quartile. 
'Ihese models were assessed by adding and testing variables and 
interactions hypothesized to be important in predicting case status. 
Previous analysis indicated that lO'iN beta-carotene levels were 
associated with increased risk of breast cancer (61). A test of the 
interaction between beta-carotene and triglyceride, and beta-carotene 
and cholesterol indicated that both interactions were significant 
predictors of case status (p<0.005 for the addition of both 
interactions) and that the interactions were related to one another 
( 17) . '!he results from the one and two interaction models were similar; 
for ease of inteJ::pretation, the results from the one interaction model 
are presented. 
Table 4 summarizes the cholesterol by beta-carotene interaction. 
Within the highest cholesterol level, lO'iN beta-carotene was associated 
with an increased risk of breast cancer, and risk decreased as beta-
carotene increased. A slightly elevated odds ratio was apparent within 
the median cholesterol level, in combination with lO'iN beta-carotene, 
hO'iNever this confidence interval included unity. In contrast to the 
results from the main effect analysis, these results from the 
interaction analysis suggest an increased risk of breast cancer 
associated with the combination of higher cholesterol and lower beta-
carotene values. 
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'!he evaluation of the triglyceride by beta-carotene interaction is 
shCM.n in Table 5. '!here were no increased risks observed within the 
low triglyceride level, but a markedly increased risk associated with 
high triglyceride and low beta-carotene. '!here was also a suggestion of 
increased risk associated with low beta-carotene and the median level of 
triglyceride. 
Di..c::cnssian 
Plasma Triglycerides 
High triglyceride values in fasting blood samples were associated 
with breast cancer. Previous studies have found both elevated (30,62) 
and normal plasma triglyceride values (31, 32) in breast cancer patients 
compared with controls. It is unclear whether there is a metabolic 
alteration due to the malignancy, dietcu:y differences, or other factors 
resulting in higher triglyceride values among breast cancer cases. 
One explanation for the high triglyceride values in our study is the 
possible presence of cachectin or "tumor necrosis factor" in some cases. 
cachectin has been shown to inhibit lipoprotein lipase and thus inhibit 
clearance of triglycerides (63). Although there is some indication that 
cachectin may be present in small quantities early in the disease 
process, it is more prominent when wasting is observed in the later 
stages of disease (64). Wasting was not evident in the newly diagnosed 
cancers in this study, and in fact, the cases had relatively high 
Quetelet's index (mean ± SD = 25.8 ± 5.2). '!here was no trend of 
decreasing Quetelet' s index with stage of disease, which provides 
indirect evidence that the disease or the malignancy was not mediating 
9 
the higher triglyceride levels. '!his fact, together with the higher 
mean triglyceride values in the earlier stages of disease, and the lack 
of a significant test for trerrl in triglyceride levels with stage of 
disease in this and another study ( 62) argue against an effect of 
cachectin. 
These higher triglyceride values ma.y be attributed to dietary 
differences among the cases. Studies have shown that higher 
triglyceride values are associated with diets higher in total fat (45), 
saturated fat (45,46,48,50,51,65) and simple carbOhydrates (45,66. 
Williams et al (67) showed that diets low in polyunsaturated fat and 
plant-protein, and high in animal-protein were associated with high 
triglyceride levels. In the present study, the observed association of 
higher plasma cholesterol and lower plasma beta-carotene values with 
breast cancer supports the concept of cases consuming diets higher in 
saturated fat, animal protein and lower in polyunsaturated fat and in 
carotene-containing vegetables compared to controls. The dietary 
analysis in this study (17) demonstrated a lower intake of 
polyunsaturated fat among cases, although no association was evident 
between saturated fat and case status. 
Higher triglyceride values also ma.y be related to the honnonal 
enviromnent. Elevated triglyceride values have been associated with 
oral contraceptive use (68), estrogen treatment (69, 70) and the 
ovulato:ry phase of the menstrual cycle (71). A post hoc test 
controlling for exogenous estrogen use did not alter the results of 
higher triglyceride levels in cases compared with controls. However, 
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the elevated triglyceride levels ma.y be an irx:licator of an envirornnent 
higher in circulating estrogens. 
Plasma Cholesterol 
'!his study revealed that both high arrl lCJW' cholesterol levels were 
associated with breast cancer but most likely in very different ways. 
'!he apparent disparity can be reconciled by the flCJW' diagram of 
hypothesized events shown in Figure 1. '!he intake of diets low in 
carotene-containing vegetables arrl high in saturated fats results in 
plasma. that is low in beta-carotene arrl high in cholesterol arrl 
triglyceride levels. '!he combination of low beta-carotene arrl high 
cholesterol is associated with breast cancer, which is consistent with 
results from the evaluation of this interaction. After development and 
progression of the breast cancer, the disease process causes the 
cholesterol levels to be lowered. '!his is consistent with the observed 
lower cholesterol levels among breast cancer patients with more advanced 
disease. 
'lhree investigations support these findings (30, 31, 72}. Compared 
with the control groups, women with early stage breast cancers were 
shown to have higher cholesterol values (30,72}, whereas women with 
metastatic breast cancer were shown to have lower cholesterol values 
(31). No association between plasma. cholesterol and breast cancer was 
reported in a fourth investigation (32}; this study was lilnited by 
small sample size (17 cases and 16 controls, power<50%), however. 
'!he observed trend of decreasing cholesterol with increasing 
severity of disease in the present study is consistent with a metabolic 
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alteration of cholesterol values caused by the disease. Although the 
trerrl of lower cholesterol values with more advanced disease has been 
observed in colon cancer (73), no evidence was fourrl for this 
phenomenon in breast cancer (74). Several cohort studies, however, 
suggested a preclincial effect (36,39,40). Only one study (39) 
suggested a preclinical cholesterol effect in breast cancer, but these 
results were not significant. In the Iowa cohort (36) , the mean 
cholesterol values were 12 rrgjdl lower in female cases diagnosed within 
2 years of the blc:xxl drawing compared with cases diagnosed later but 
these authors did not detennine the statistical significance of this 
difference. There was also a suggestion of a preclinical effect in 
overall cancers in women in the NHANFS data (40). 
Although the mechanism remains to be elucidated, cholesterol may be 
metabolized more quickly during the disease process resulting in lowered 
plasma levels. Hill et al (75) and Gorbach (76) have postulated that 
breast cancer patients may have increased conversion of biliru::y steroids 
into estrogens that could become reabsorbed. MacMahon and coworkers 
(77) reported that urinru::y estrogen excretion was higher among cases 
carrprred to controls, suggesting higher plasma estrogen levels. Plasma 
studies have been inconsistent, but evaluation of populations at low and 
high-risk of breast cancer support the concept of higher plasma estrogen 
levels in high-risk populations (78). Another explanation for the 
lower cholesterol in the cases could be an aberration in the 
enterohepatic circulation. There may be increased loss of cholesterol 
via fecal bile acids and neutral steroids as has been noted in breast 
cancer (79) and colon cancer patients (80} • 
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Alternatively, the lower cholesterol levels may be unrelated to 
metabolic disturbances, perhaps beinJ of genetic andjor dietal:y origin. 
'!he trerxi in stage could be explained by a more rapid progression of the 
disease, with less opportunity for early detection arrl a later stage of 
cancer at diagnosis. '!his hypothesis could best :be tested usinJ 
prospective data with periodic blood samples arrl consistent screening. 
Commentary 
'!he ma.in effect of cholesterol was only marginally significant arrl 
in:licated that lower cholesterol was asscx:::iated with case status. '!he 
interaction with :beta-carotene was highly significant, however, and 
described the relationship :between these nutrients arrl breast cancer 
more precisely. 'Ihese results demonstrate the importance of 
investigatinJ nutrient-nutrient interactions in relation to cancer risk. 
Although there are difficulties in interpretinJ statistical interactions 
(81-83), nutrients are known to interact with one another biologically, 
ma.kinJ it prudent to investigate interactions and describe the 
conditional nature of the effect more fully. 
'!he increased risk associated with low :beta-carotene is consistent 
with cases consuming diets lower in carotene-containing vegetables 
because plasma beta-carotene has :been shown to reflect dietal:y intake of 
carotenes (84-86). Furthennore, this risk is higher in combination 
with the higher plasma lipid levels suggestinJ an interrelationship 
between these nutrients and carcinogenesis. 'lhese findings are 
intriguinJ and deserve further attention. 
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Table 1 
Effect of diagnosis and stage on mean values of 
plasma cholesterol (mg/dl) and triglycerides (mg/dl) 
Cholesterol Triglycerides 
Group N Mean (SD) N Mean (SD) 
General Diagnoses 
Controls 101 237 (53) 100 99 (55)** 
Cases 81 233 (48) 81 123 (64) 
Cancer Stages 
In Situ 6 253 (71) 6 141 (55) 
Stage I 26 245 (53) 25 122 (51) 
Stage II 37 225 (36) 37 128 (78) 
Stage III+IV 12 221 (54)* 12 105 (39) 
* Significant (p=0.02) test for trend with "specific" stages 
** Controls significantly (p=O.OOI) different from cases 
Table 2 
Changes in the case-control odds ratios for 
cholesterol quartiles with adjustments for other variables 
Cholesterol Quartiles 
High Low 
Adjustment Q1 Q2 Q3 Q4a 
Unadjusted o.85c d 0.53 0.70 1.00 {0.38, 1.87) {0.23,1.27) {0.31,1.57) 
Other risk 0.41 0.24 0.45 1.00 
Factorse (0.14,1.14) {0.08,0.73) (0.16, 1. 28) 
Other risk 
Factors 0.38 0.26 0.52 1.00 
Triglyceride (0.12, 1.16) {0.08,0.85) {0.18,1.56) 
Beta-carotene 
a Reference group 
b Test for trend across quartiles 
c Odds ratio of quartile compared with the fourth quartile 
d 95% confidence limits 
Trendb 
p-value 
0.60 
0.03 
0.03 
e Adjusted for age, age at first birth, family history, menarche, 
Quetelet index, parity, age at menopause, income and marital 
status. 
Table 3 
Changes in the case-control odds ratios for 
triglyceride quartiles with adjustments for other variables 
Trigl~ceride guartiles 
Adjustment 
Unadjusted 
Other Risk 
Factorse 
Other Risk 
Factors 
Cholesterol 
Beta-carotene 
High 
Q1 
3.9oc d (1.60,9.49) 
2.84 
(0.82,9.87) 
4.19 
(0.99,17.6) 
a Reference quartile 
Q2 
1.70 
(0.65,4.43) 
1.08 
(0.31,3.85) 
1.57 
(0.40,6.10) 
b Test for trend of across quartiles 
c Odds ratio 
d 95% confidence limits 
Q3 
1.50 
(0.57,3.97) 
1.39 
(0.41,4.68) 
1.64 
(0.45,5.94) 
Low Trendb Q4a p-value 
1.00 <0.01 
1.00 0.10 
1.00 0.07 
e Adjusted for age, age at first birth, family history, parity, 
age at menarche, Quetelet's index, age at menopause, income 
and marital status. 
Table 4 
Case-control adjusteda odds ratios with 3 reference groups 
for the beta-carotene by cholesterol interaction 
Cholesterol 
Level 
(percentile)b 
Median (50) 
High (75) 
Odds Ratios CCI) 
Beta-Carotene guartiles 
Low 
Q1 Q2 Q3 
0.33 0.18 0.12 
(0.04,2.97) ( 0. 02, 1. 79) (0.01,1.16) 
[6/7]e [6/6] [6/5] 
1.53 0.66 0.44 
(0.35,6.61) (0.15,2.83) (0.11, 1.86) 
[12/15] [6/12] [5/16] 
5.99 2.04 1.40 
(1.10,32.6) (0.48,8.73) (0.33,5.93) 
[6/3] [5/7] [7/4] 
High Q4C 
1.00 
[1/2] 
1.00 
[6/12] 
1.00 
[4/11] 
a Adjusted for age, age at first birth, family history, age at 
menarche, Quetelet index, parity, age at menopause, income, 
marital status, beta-carotene, triglyceride, plus the beta-
carotene by triglyceride and beta-carotene by cholesterol 
interactions; triglyceride held constant at its mean. 
b Percentile based on ranking of all study subjects 
c Reference group 
d Low= 196 mg/dl, Median= 228 mg/dl, High= 262 mg/dl 
e Number cases/controls 
Table 5 
Case-control adjusteda odds ratios with one reference group 
for the beta-carotene by triglyceride interaction 
Triglyceride 
level 
(percentile)b 
Median (50) 
High (75) 
low 
Q1 
0.83 
(0.16,4.40) 
[3/9]e 
2.69 
(0.71,10.3) 
[15/12] 
8.86 
( 1.81 '43 .3) 
[17/4] 
Odds Ratios CCI) 
Beta-Carotene guartiles 
High 
Q2 Q3 Q4 
1.04 1.14 1.ood 
(0.20,5.38) (0.27,4.86) 
[4/7] [3/7] [2/7] 
1.52 0.96 1.00 
(0.42,5.52) (0.27,3.43) 
[7/13] [12/15] [6/13] 
2.23 0.82 1.00 
(0.50,9.90) (0.17,4.01) 
[6/5] [3/3] [3/5] 
a Adjusted for age, age at first birth, family history, age at 
menarche, Quetelet index, parity, age at menopause, income, 
marital status, cholesterol, beta-carotene, plus the beta-
carotene by triglyceride and beta-carotene by cholesterol 
interactions; cholesterol held constant at its mean. 
b Percentile based on ranking of all study subjects 
c low= 67 mg/dl, Median= 95 mg/dl, High= 136 mg/dl 
d Reference group 
e Number cases/controls 
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Figure 1. Flow diagram of the hypothesized association between three plasma nutrients and 
breast cancer. Direct arrows indicate direct associations, arrow on arrow indicates 
effect modification, dotted arrows indicate risk factors not evaluated in this 
investigation. 
